Vaxcyte commences offerings of common stock, warrants and notes
Vaxcyte Inc. announced the commencement of proposed offerings of common stock, pre-funded warrants, and convertible senior notes, aiming to raise funds for clinical development of its Vax-31 programs, manufacturing scale-up, and potential PCV program launches.
Vaxcyte said on Oct. 5 it has started proposed public offerings of common stock, pre-funded warrants and convertible senior notes. The company said the two offerings are for $500 million of common stock and $500 million of convertible notes. S.
Vax-31 launch.